NewLink Genetics Corp. will receive an additional $18 million from the U.S. Department of Health and Human Services to boost the manufacture of its potential Ebola vaccine. The Ames company said today in a release that it originally received a $30 million grant to assist with research and development. Clinical trials are ongoing. The vaccine originally was developed by the Public Health Agency of Canada and was subsequently licensed to a subsidiary of NewLink Genetics. In late 2014, Merck & Co. Inc. licensed the vaccine from NewLink Genetics to apply Merck’s vaccine expertise to help accelerate its development.